(LOS ANGELES) –In a landmark move for biomedical progress, the Terasaki Institute for Biomedical Innovation (TIBI) today unveiled the launch of four pioneering startup companies. These ventures represent a strategic leap forward in TIBI's commitment to transforming healthcare through innovation. By harnessing the institute's groundbreaking research in biomaterials, micro-needles, organoids, tissue engineering, and advanced biosensing, these startups are poised to tackle some of the most pressing health challenges of our time.
Introducing the Future of Biomedical Solutions:
- BioOptix: Revolutionizing ocular health, BioOptix is at the forefront of creating smart contact lenses capable of delivering medications for severe eye conditions, including glaucoma. These lenses are equipped with state-of-the-art monitoring and sensing technology, enabling precise treatment modulation directly to the eye.
- Digital Immunology: At the intersection of technology and immunology, Digital Immunology is pioneering the use of cutting-edge biomaterials, high-throughput digital culture platforms, organoid technology, and artificial intelligence. This innovative approach accelerates the development of targeted immunotherapies and vaccines to combat cancer and a spectrum of other diseases.
- OnVagus: Introducing a breakthrough in neural health, OnVagus is developing a non-invasive, wearable patch that disrupts harmful vagus nerve signaling associated with cancer-induced weight loss and muscle atrophy. This signaling contributes to one-third of all cancer fatalities. The OnVagus patch offers a drug-free alternative that holds promise for treating not only cancer-related symptoms but also obesity, autoimmune disorders, and metabolic diseases.
- Surgi-Zipper: Redefining surgical recovery, Surgi-Zipper's innovative flexible patch provides a secure, leak-proof closure for air- or fluid-filled organs post-operation. Its unique biodegradable, double-layered design features a non-adhesive outer layer coupled with an inner layer that adheres to moist internal surfaces. The Surgi-Zipper is designed to remove tension from the surgical suture line in non-planar dynamic tissues and enhance healing, with potential applications extending to cardiovascular and pulmonary surgeries. The unique .chemical interactions between the adhesive layer and tissue allow ease of application and on-demand removal of the patch with laparoscopy or open surgery
Ali Khademhosseini, the esteemed Director and CEO of TIBI, expressed his enthusiasm: "The launch of these four startups marks a significant milestone in TIBI's journey towards bringing our advanced biomedical research to the forefront of medical application. We are thrilled to see our vision of rapid innovation translation come to life, offering tangible solutions that will improve health outcomes and patient care."
The Terasaki Institute for Biomedical Innovation remains dedicated to its mission of pioneering breakthroughs in biomedical science and technology. With the establishment of these startups, TIBI is not just envisioning the future of medicine—it is actively creating it.